Sionna Therapeutics announced that its Phase 2a trial for SION-719, combined with Trikafta, failed to meet its key endpoint of reducing sweat chloride in cystic fibrosis patients. Following this announcement on August 10, 2026, the company's stock price dropped sharply by 91.18%. This significant decline has led Pomerantz LLP to investigate potential securities fraud or unlawful practices by Sionna and its executives. Investors affected are encouraged to contact the law firm for possible class action participation.
Sionna Therapeutics saw its stock price plunge 91.18% after a failed Phase 2a trial announcement. For readers following the health sector, here is Pluang's market snapshot as of Oct 01, 2026 20:52 WIB: out of 100 priced US health stocks, 30 rose and 67 fell. Notable movers include AMWL at USD 13.01 with a 4.20% drop and 100% sell order activity, CAH at USD 231.18 with a 4.14% gain and 100% buy order activity, and TLRY at USD 3.61 with a 3.73% decline and 99% sell order activity.
National Healthcare Properties (NHP) announced that Lindsay Gordon, its Executive Vice President and Head of Senior Housing, has been elected to the executive board of the American Senior Housing Association (ASHA). ASHA is a leading national organiz...
Akzo Nobel reported Q3 2026 earnings with revenue of $2.85 billion and EPS of $0.38, both below analyst estimates of $2.96 billion and $0.42 respectively. Despite these misses, the company's core profit exceeded expectations, indicating underlying st...
United Airlines reported a strong third-quarter revenue of $17.9 billion, up 17.4% year-over-year, and provided optimistic guidance for the fourth quarter. Jefferies raised its price target for United Airlines stock to $142 from $134, suggesting a 36...
OFG Bancorp reported third-quarter earnings per share of $1.33, surpassing analyst estimates of around $1.23. However, its revenue came in slightly below expectations at $185.7 million versus estimates near $187 million. The earnings beat was driven ...
SEI Investments is set to report its Q3 2026 earnings on October 21 after market close, with analysts projecting earnings per share of $1.59 and revenue of $658.54 million. These estimates indicate a strong year-over-year growth of 22.3% in earnings ...
